Objective: To evaluate the 3-year clinical outcomes and durability of photoselective vaporization of the prostate (PVP) with the GreenLight HPS laser in the treatment of symptomatic and obstructive benign prostatic hyperplasia (BPH). Methods: A total of 78 patients underwent PVP with the GreenLight HPS laser from October 2007 to November 2008. The baseline and treatment outcomes after surgery were evaluated 3 years later with the International Prostate Symptom Score (IPSS), quality of life (QoL), maximum flow rate (Qmax), postvoid residual rate (PVR), and transrectal ultrasound-determined prostate volume. These parameters were assessed at 1, 3, 6, 12, 24, and 36 months. Results: Patients’ urinary symptoms and QoL significantly improved after surgery. The functional outcomes showed immediate and stable improvements during the entire follow-up period. At 36 months, the average percentage of improvements compared with baseline was as follows: IPSS, 60.2%; QoL, 80.9%; Qmax, 138.7%, and PVR, 82.6%. The median prostate volume, evaluated by transrectal ultrasonography, showed a 50.4% reduction when compared to preoperative volume. Overall, complications from surgery were low; only 6.7% of the 75 patients required reoperation during the 3-year follow-up. Conclusion: PVP using the GreenLight HPS laser showed a safe and effective treatment outcome for the treatment of symptomatic and obstructive BPH.

Keywords:
Photoselective vaporization of the prostate, Benign prostatic hyperplasia, GreenLight HPS laser
1.
Chen CH, Chiang PH, Chuang YC, Lee WC, Chen YT, Lee WC: Preliminary results of prostate vaporization in the treatment of benign prostatic hyperplasia by using a 200-W high-intensity diode laser. Urol 2010;75:659–663.
2.
Stafinski T, Menon D, Harris K, Gray G, Jhangri G: Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia. CUAJ 2008;2:124–134.
3.
Nuhoğlu B, Balci MB, Aydin M, Hazar I, Onuk Ö, Taş T, Fikri O: The role of bipolar transurethral vaporization in the management of benign prostatic hyperplasia. Urol Int 2011;87:400–404.
4.
Costello AJ, Bowsher WG, Bolton DM, Braslis KG, Burt J: Laser ablation of the prostate in patients with benign prostatic hypertrophy. Br J Urol 1992;69:603–608.
5.
Kuntz RM: Current role of lasers in the treatment of benign prostatic hyperplasia. Eur Urol 2006;49:961–969.
6.
Kuntz RM: Laser treatment of benign prostatic hyperplasia. World J Urol 2007;25:241–247.
7.
Sountoulides P, de la Rosette: Update on photoselective vaporization of the prostate. Curr Urol Rep 2008;9:106–112.
8.
Wasson JH, Reda DJ, Bruskewitz RC, Elison J, Keller AM, Henderson WG: A comparison of transurethral surgery with watchful waiting for moderate symptom of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on transurethral resection of the prostate. N Engl J Med 1995;332:75–79.
9.
Rorborglu PG, Kane CJ, Ward JF, Roberts JL, Sands JP: Immediate and postoperative complications of transurethral prostatectomy in the 1990s. J Urol 1999;162:1307–1310.
10.
Madersbacher S, Lackner J, Brossner C, Rohlich M, Stancik L, Willinger M, et al; Prostate Study Group of the Austrian Society of Urology: Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23,123 cases. Eur Urol 2005;47:499–504.
11.
Rassweiler J, Teber D, Kuntz R, Hofmann R: Complications of transurethral resection of the prostate (TURP) – incidence, management, and prevention. Eur Urol 2006;50:969–980.
12.
Ogden CW, Reddy P, Johnson H, Romsay JWA, Carter C: Sham versus transurethral microwave thermotherapy in patients with symptoms of benign prostatic bladder outflow obstruction. Lancet 1993;341:14–17.
13.
Zlotta AR, Giannakopoulos X, Maehlum O, Ostrem T, Schulman CC: Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 2003;44:89–93.
14.
Spaliviero M, Araki M, Wong C: Short- term outcomes of Greenlight HPS™ laser photoselective vaporization prostatectomy (PVP) for benign prostatic hyperplasia (BPH). J Endourol 2008;22:2341–2347.
15.
Teichmann HO, Herrmann TR, Bach T: Technical aspects of lasers in urology. World J Urol 2007;25:221–225.
16.
Pal RP, Khan MA: Intermediate-term efficacy of Tm:YAG laser prostate vaporesection for bladder outlet obstruction: initial experience from a UK teaching hospital. Urol Int 2012;88:39–42.
17.
Zhang B, Wu G, Chen C, Song B, Li X, Zhong L, Wang H: Combination of channel-TURP and ILC versus standard TURP or ILC for elderly with benign prostatic hyperplasia: a randomized prospective trial. Urol Int 2011;87:392–399.
18.
Kumar SM: Rapid communication: holmium laser ablation of large prostate glands: an endourologic alternative to open prostatectomy. J Endourol 2007;21:659–662.
19.
Bach T, Herrmann TR, Ganzer R, Burchardt M, Gross AJ: RevoLix vaporesection of the prostate: initial results of 54 patients with a 1-year follow-up. World J Urol 2007;25:257–262.
20.
Ruszat R, Seitz M, Wyler SF, Abe C, Rieken M, Reich O, et al: Greenlight laser vaporization of the prostate: single-center experienced long-term results after 500 procedures. Eur Urol 2008;54:893–901.
21.
Lee R, Gonzalez RR, TE AE: The evolution of photoselective vaporization prostatectomy (PVP): advancing the surgical treatment of benign prostatic hyperplasia. World J Urol 2006;24:405–409.
22.
Te AE: The next generation in laser treatments and the role of the GreenLight high-performance system laser. Rev Urol 2006;8:S24–S30.
23.
Muir G, Sancha FG, Bachmann A, Choi B, Collins B, Rosette J, et al: Techniques and training with GreenLight HPS 120-W laser therapy of the prostate: position paper. Eur Urol suppl 2008;7:370–377.
24.
Hai MA: Photoselective vaporization of prostate: five-year outcomes of entire clinic patient population. Urol 2009;73:807–810.
25.
Te AE, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO, Hais MA: Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years. BJU Int 2006;97:1229–1233.
26.
Woo H, Reich O, Bachmann A, Choi B, Collins E, Rosette J, et al: Outcomes of GreenLight HPS 120-W laser theraphy in specific patients populations: those in retention, on anticoagulants, and with large prostates (>80 ml). Eur Urol Suppl 2008;7:378–383.
27.
Al-Ansari A, Younes N, Sampige VP, et al: GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up. Eur Urol 2010;58:349–355.
28.
Capitan C, Blazquez C, Martin MD, Hernandez V, de la Pena E, Llorente C: GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: a randomized clinical trial with 2-year follow-up. Eur Urol 2011;60:734–739.
29.
Tasci AL, Llbey YO, Luleci H, Cicekler O, Sahin S, Cevik C et al: 120-W GreenLight Laser photoselective vaporization of prostate for benign prostatic hyperplasia: midterm outcomes. Urol 2010;78:134–140.
30.
Gu X, Storm K, Spaliviero M, Wong C: Intermediate outcomes of GreenLight HPS™ laser photoselective vaporization prostatectomy for symptomatic benign prostatic hyperplasia. J Endourol 2011;25:1037–1041.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.